Riverwater Partners, an investment management company, released its 'Small Cap Strategy' Q2 2026 investor letter. The letter can be downloaded here. The Small Cap Strategy underperformed the Russell 2000 in the second quarter as the benchmark experienced one of its strongest risk-on rallies in recent memory, although the strategy remained ahead year-to-date. The quarter was defined by accelerating AI investment, energy market disruptions, and renewed investor appetite for higher-beta stocks, creating headwinds for the firm's quality-focused approach and healthcare positioning. Despite this, stock selection contributed positively in energy, materials, and financials, while healthcare and consumer discretionary detracted due to the fund's disciplined avoidance of speculative businesses. Looking ahead, the firm remains cautiously optimistic, focusing on opportunities created by market dislocations, including AI infrastructure enablers, select consumer companies, healthcare innovators, and energy businesses trading below intrinsic value. The strategy continues to emphasize high-quality companies with strong management teams and attractive valuations, positioning the portfolio for a potential rotation away from speculative market leadership. In addition, please check the Strategy's top five holdings to know its best picks in 2026.
In its second-quarter 2026 investor letter, Riverwater Partners Small Cap Strategy highlighted Stevanato Group S.p.A. (NYSE:STVN) as a new holding. Stevanato Group S.p.A. (NYSE:STVN) is an Italian company that designs and distributes products and processes that offer integrated solutions for the biopharma and healthcare industries. On August 31, 2026, Stevanato Group S.p.A. (NYSE:STVN) closed at $21.03 per share. Stevanato Group S.p.A. (NYSE:STVN) gained 9.06% in the past month while its shares lost 5.39% over the past 52 weeks. Stevanato Group S.p.A. (NYSE:STVN) has a market capitalization of $5.85 billion and its stock has traded within a 52-week range of $12.89 to $28.00.
Riverwater Partners Small Cap Strategy stated the following regarding Stevanato Group S.p.A. (NYSE:STVN) in its Q2 2026 investor letter:
"In addition, we initiated positions in Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The stock sold off following the launch of oral GLP-1s, which many believe will end the need for injectable forms. Experts believe an expanding GLP-1 TAM, coupled with varying use cases, will necessitate ongoing need for injectable forms. Indeed, 25% of drugs approved in 2025 were biologics which will require injectable devices. This market overreaction offered an attractive entry valuation of 12.5x FY2026E EBITDA vs. STVN's historic multiple of 20X and its nearest comp West Pharmaceutical (WST) at approximately 22–25x."
#NYSE #strategy #market #riverwater
In its second-quarter 2026 investor letter, Riverwater Partners Small Cap Strategy highlighted Stevanato Group S.p.A. (NYSE:STVN) as a new holding. Stevanato Group S.p.A. (NYSE:STVN) is an Italian company that designs and distributes products and processes that offer integrated solutions for the biopharma and healthcare industries. On August 31, 2026, Stevanato Group S.p.A. (NYSE:STVN) closed at $21.03 per share. Stevanato Group S.p.A. (NYSE:STVN) gained 9.06% in the past month while its shares lost 5.39% over the past 52 weeks. Stevanato Group S.p.A. (NYSE:STVN) has a market capitalization of $5.85 billion and its stock has traded within a 52-week range of $12.89 to $28.00.
Riverwater Partners Small Cap Strategy stated the following regarding Stevanato Group S.p.A. (NYSE:STVN) in its Q2 2026 investor letter:
"In addition, we initiated positions in Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The stock sold off following the launch of oral GLP-1s, which many believe will end the need for injectable forms. Experts believe an expanding GLP-1 TAM, coupled with varying use cases, will necessitate ongoing need for injectable forms. Indeed, 25% of drugs approved in 2025 were biologics which will require injectable devices. This market overreaction offered an attractive entry valuation of 12.5x FY2026E EBITDA vs. STVN's historic multiple of 20X and its nearest comp West Pharmaceutical (WST) at approximately 22–25x."
#NYSE #strategy #market #riverwater
1 day ago
